Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients

Pharmacology

Volumn 75, Issue 4, 2005, Pages 165-178

  Kulemann, Vanessa ^a   Bauer, Martin ^a   Graninger, Wolfgang ^a   Joukhadar, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Caspofungin; Multimorbid patients; Voriconazole

Indexed keywords

AMPHOTERICIN B; ASTEMIZOLE; AZITHROMYCIN; CARBAMAZEPINE; CASPOFUNGIN; CIMETIDINE; CISAPRIDE; CYCLOSPORIN A; DELAVIRDINE; DIGOXIN; EFAVIRENZ; ERYTHROMYCIN; FLUCONAZOLE; GLUCOCORTICOID; INDINAVIR; ITRACONAZOLE; METHADONE; MYCOPHENOLIC ACID; OMEPRAZOLE; PHENYTOIN; PIMOZIDE; PREDNISOLONE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; TACROLIMUS; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DIZZINESS; DRUG ANTAGONISM; DRUG FEVER; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ERGOTISM; FOOD DRUG INTERACTION; HALLUCINATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; INJECTION SITE REACTION; INTENSIVE CARE; LIVER DYSFUNCTION; MORBIDITY; NAUSEA; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PHLEBITIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RASH; REVIEW; RISK ASSESSMENT; SHIVERING; SIDE EFFECT; SKIN MANIFESTATION; TORSADE DES POINTES; VISUAL DISORDER; VOMITING; WEAKNESS; XEROSTOMIA;

ANTI-BACTERIAL AGENTS; ANTICONVULSANTS; ANTIFUNGAL AGENTS; CLINICAL TRIALS; CROSS INFECTION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG MONITORING; FOOD-DRUG INTERACTIONS; HUMANS; IMMUNOCOMPROMISED HOST; INTENSIVE CARE UNITS; LIVER; MYCOSES; PEPTIDES, CYCLIC; POLYPHARMACY; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; TRIAZOLES;

EID: 31544473479     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088622     Document Type: Review

References (78)

1. Graedon J, Graedon T: Deadly Drug Interactions: The People's Pharmacy Guide. New York, St. Martin's Griffin, 1995.
2. Calandra T, Marchetti O: Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis 2004;39(suppl 4):S185-S192.
3. Duchini A, Redfield DC, McHutchison JG, Brunson ME, Pockros PJ: Aspergillosis in liver transplant recipients: successful treatment and improved survival using a multistep approach. South Med J 2002;95:897-899.
4. Silling G, Fegeler W, Roos N, Essink M, Buchner T: Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. Mycoses 1999;42(Suppl 2):101-104.
5. Maschmeyer G: Interventional antimicrobial therapy in febrile neutropenic patients. Diagn Microbiol Infect Dis 1999;34:205-212.
6. Klastersky J: Prevention and therapy of fungal infections in cancer patients: a review of recently published information. Support Care Cancer 1995;3:393-401.
7. Albengres E, Le Louet H, Tillement JP: Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998;18:83-97.
8. Deray G: Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002;49(suppl 1):37-41.
9. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH: The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001;111:528-534.
10. Rapp RP: Changing strategies for the management of invasive fungal infections. Pharmacotherapy 2004;24:4S-28S; quiz 29S-32S.
11. Eriksson U, Seifert B, Schaffner A: Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322:579-582.
12. Klastersky J: Empiric antimicrobial therapy for febrile granulocytopenic cancer patients. Lessons from four EORTC trials. Acta Oncol 1988;27:497-502.
13. Bohme A, Just-Nubling G, Bergmann L, Shah PM, Stille W, Hoelzer D: Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1996;38:953-961.
14. Marr KA: Antifungal prophylaxis in hematopoietic stem cell transplant recipients. Curr Opin Infect Dis 2001;14:423-426.
15. Stemmer SM, Maor Y, Hardan I: Oral fluconazole for empiric treatment of prolonged fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation. Am J Clin Oncol 2004;27:328-332.
16. Wingard JR, Leather HL: Empiric antifungal therapy for the neutropenic patient. Oncology (Huntingt) 2001;15:351-363; discussion 363-364. 367-369.
17. Walsh TJ, Lee JW: Prevention of invasive fungal infections in patients with neoplastic disease. Clin Infect Dis 1993;17(suppl 2):S468-S480.
18. Edwards JE Jr, Bodey GP, Bowden RA, Buchner T, de Pauw BE, Filler SG, Ghannoum MA, Glauser M, Herbrecht R, Kauffman CA, Kohno S, Martino P, Meunier F, Mori T, Pfaller MA, Rex JH, Rogers TR, Rubin RH, Solomkin J, Viscoli C, Walsh TJ, White M: International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997;25:43-59.
19. Deresinski SC, Stevens DA: Caspofungin. Clin Infect Dis 2003;36:1445-1457.
20. Johnson LB, Kauffman CA: Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-637.
21. Sobel JD: Practice guidelines for the treatment of fungal infections. For the Mycoses Study Group. Infectious Diseases Society of America. Clin Infect Dis 2000;30:652.
22. Stone EA, Fung HB, Kirschenbaum HL: Caspofungin: an echinocandin antifungal agent. Clin Ther 2002;24:351-377; discussion 329.
23. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR: Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240-248.
24. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA: Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41:3623-3626.
25. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
26. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A: Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002;42:395-402.
27. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-2029.
28. Sable CA, Nguyen BY, Chodakewitz JA, Di-Nubile MJ: Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002;4:25-30.
29. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA: Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002;46:739-745.
30. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N: Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004;48:2166-2172.
31. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-234.
32. Boucher HW, Groll AH, Chiou CC, Walsh TJ: Newer systemic antifungal agents: Pharmacokinetics, safety and efficacy. Drugs 2004;64:1997-2020.
33. Cesaro S, Toffolutti T, Messina C, Calore E, Alaggio R, Cusinato R, Pillon M, Zanesco L: Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 2004;73:50-55.
34. Manavathu EK, Ramesh MS, Baskaran I, Ganesan LT, Chandrasekar PH: A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004;53:386-389.
35. Ullmann AJ: Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin 2003;19:263-271.
36. Denning DW: Echinocandins and pneumocandins - a new antifungal class with a novel mode of action. J Antimicrob Chemother 1997;40:611-614.
37. Kartsonis NA, Nielsen J, Douglas CM: Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat 2003;6:197-218.
38. Wingard JR, Leather H: A new era of antifungal therapy. Biol Blood Marrow Transplant 2004;10:73-90.
39. Letscher-Bru V, Herbrecht R: Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003;51:513-521.
40. Merck & Co: CANCIDAS Prescribing Information. Whitehouse Station, Merck, 2004.
41. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
42. Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC: Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004;48:815-823.
43. Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA: Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005;50:196-205.
44. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563-1571.
45. Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lasseter KC, Kraft WK, Greenberg H, Waldman SA: Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004;48:4306-4314.
46. Pfizer: VFEND US Prescribing Information. Distributed by ROERIG, Division of Pfizer, New York, 2004.
47. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB: Voriconazole. Clin Ther 2003;25:1321-1381.
48. Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, Hodges M, Troke P, Romero AJ: A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447-1454.
49. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-571.
50. Lutsar I, Roffey S, Troke P: Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003;37:728-732.
51. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW: Adverse reactions to voriconazole. Clin Infect Dis 2004;39:1241-1244.
52. Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH: Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 2004;26:534-540.
53. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, Woosley RL, Flockhart DA: The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-669.
54. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A: Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003;56(suppl 1):37-44.
55. Purkins L, Wood N, Kleinermans D, Love ER: No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol 2003;56(suppl 1):62-68.
56. Purkins L, Wood N, Kleinermans D, Nichols D: Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 2003;56(suppl 1):24-29.
57. Wood N, Tan K, Purkins L, Layton G, Hamlin J, Kleinermans D, Nichols D: Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003;56(suppl 1):56-61.
58. FDA: Background document for the Antiviral Drug Advisory Committee meeting October 4, 2001: Voriconazole tablets and voriconazole injection, Pfizer Global Research and Development NDAs 21-266 and 21-267, 2002.
59. Wang LS, Zhu B, El-Aty AM, Zhou G, Li Z, Wu J, Chen GL, Liu J, Tang ZR, An W, Li Q, Wang D, Zhou HH: The influence of St John's Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 2004;44:577-581.
60. Stevens DA: Molecular epidemiology of Candida. J Clin Microbiol 2002;40:2710.
61. Ostrosky-Zeichner L: Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2004;23:739-744.
62. Pappas PG RJ, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE: Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-189.
63. Rex JH WT, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE: Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000;30:662-678.
64. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhate N, Toure Kane NC, Laniece I, Ndir A, Vergne L, Ndoye I, Mboup S, Sow PS, Delaporte E: Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 2005;38:14-17.
65. Servais J, Schmit JC, Arendt V, Lambert C, Staub T, Robert I, Fontaine E, Plesseria JM, Burgy C, Kirpach P, Schneider F, Hemmer R: Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort. HIV Clin Trials 2000;1:17-24.
66. Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, Isaacs R, Gonzalez C, McMahon D, Richman DD, Robertson M, Mellors JW: Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003;17:2345-2349.
67. Purkins L, Wood N, Ghahramani P, Kleinermans D, Layton G, Nichols D: No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. Br J Clin Pharmacol 2003;56(suppl 1):30-36.
68. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, Smietana JM, DiNubile MJ, Sable CA: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113:294-299.
69. Colomba C, Antinori S: Fungal infections in transplantation patients. Rec Prog Med 2003;94:516-528.
70. Sadaba B, Campanero MA, Quetglas EG, Azanza JR: Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004;36:3226-3228.
71. Fortun J, Martin-Davila P, Sanchez MA, Pintado V, Alvarez ME, Sanchez-Sousa A, Moreno S: Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis 2003;22:408-413.
72. Mathis AS, Shah NK, Friedman GS: Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc 2004;36:2708-2709.
73. Romero AJ, Pogamp PL, Nilsson LG, Wood N: Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71:226-234.
74. Wood N, Tan K, Allan R, Fielding A, Nichols DJ: Effect of voriconazole on the pharmacokinetics of tacrolimus. 41st Interscience Conf Antimicrobial Agents and Chemotherapy, Chicago, 2001.
75. Thervet E, Legendre C, Beaune P, Anglicheau D: Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005;6:37-47.
76. Kahan BD: Sirolimus-based immunosuppression: present state of the art. J Nephrol 2004;17(suppl 8):S32-S39.
77. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, Lopez J, Arranz R, Cisneros JM, Martino ML, Garcia-Sanchez PJ, Morales P, Olive T, Rovira M, Solano C: Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004;34:13-20.
78. Marr KA, Hachem R, Papanicolaou G, Somani J, Arduino JM, Lipka CJ, Ngai AL, Kartsonis N, Chodakewitz J, Sable C: Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004;6:110-116.